Gilead Sciences Inc. logo

Gilead Sciences Inc. (GILD)

Market Closed
16 Oct, 08:00 PM
NASDAQ (NGS) NASDAQ (NGS)
$
156. 19
-1.18
-0.7498%
$
187.44B Market Cap
17.2 P/E Ratio
0.42% Div Yield
7.76M Volume
6.22 Eps
$ 157.37
Previous Close
Add Transaction
Day Range
155.62 157.51
Year Range
114.02 160.51
Want to track GILD and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Gilead Sciences (GILD) Ascends But Remains Behind Market: Some Facts to Note

Gilead Sciences (GILD) Ascends But Remains Behind Market: Some Facts to Note

In the most recent trading session, Gilead Sciences (GILD) closed at $111.88, indicating a +0.54% shift from the previous trading day.

Zacks | 1 year ago
Why Gilead Sciences (GILD) is a Top Value Stock for the Long-Term

Why Gilead Sciences (GILD) is a Top Value Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks | 1 year ago
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know

Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know

Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.

Zacks | 1 year ago
2 Healthcare Stocks to Watch as JPMorgan Boosts Gilead Rating

2 Healthcare Stocks to Watch as JPMorgan Boosts Gilead Rating

When Wall Street analysts decide to come out of their caves and boost a certain stock, retail investors should pay attention to the motives behind the decision as it can signal a shift in sentiment toward an entire sector.

Marketbeat | 1 year ago
2 Healthcare Stocks to Watch as JPMorgan Boosts Gilead Rating

2 Healthcare Stocks to Watch as JPMorgan Boosts Gilead Rating

When Wall Street analysts decide to come out of their caves and boost a certain stock, retail investors should pay attention to the motives behind the decision as it can signal a shift in sentiment toward an entire sector.

Marketbeat | 1 year ago
GILD or AMGN: Which Is the Better Value Stock Right Now?

GILD or AMGN: Which Is the Better Value Stock Right Now?

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Gilead Sciences (GILD) and Amgen (AMGN). But which of these two companies is the best option for those looking for undervalued stocks?

Zacks | 1 year ago
Are Medical Stocks Lagging Gilead Sciences (GILD) This Year?

Are Medical Stocks Lagging Gilead Sciences (GILD) This Year?

Here is how Gilead Sciences (GILD) and AngioDynamics (ANGO) have performed compared to their sector so far this year.

Zacks | 1 year ago
Gilead Sciences (GILD) Stock Drops Despite Market Gains: Important Facts to Note

Gilead Sciences (GILD) Stock Drops Despite Market Gains: Important Facts to Note

The latest trading day saw Gilead Sciences (GILD) settling at $106.67, representing a -0.38% change from its previous close.

Zacks | 1 year ago
Gilead Sciences (GILD) Suffers a Larger Drop Than the General Market: Key Insights

Gilead Sciences (GILD) Suffers a Larger Drop Than the General Market: Key Insights

In the closing of the recent trading day, Gilead Sciences (GILD) stood at $105.87, denoting a -1.53% change from the preceding trading day.

Zacks | 1 year ago
GILD Stock Down on Report of Cut in HIV Prevention Spending

GILD Stock Down on Report of Cut in HIV Prevention Spending

Gilead Sciences takes a hit after a Wall Street Journal reports state that the Trump administration is looking to slash funding for HIV prevention in the country.

Zacks | 1 year ago
Brokers Suggest Investing in Gilead (GILD): Read This Before Placing a Bet

Brokers Suggest Investing in Gilead (GILD): Read This Before Placing a Bet

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

Zacks | 1 year ago
Gilead Dives As HHS Reportedly Mulls Cutting HIV Prevention Funding

Gilead Dives As HHS Reportedly Mulls Cutting HIV Prevention Funding

Gilead stock tumbled Wednesday on reports HHS could slash federal funding for HIV prevention, a staple in Gilead Sciences' topline. The post Gilead Dives As HHS Reportedly Mulls Cutting HIV Prevention Funding appeared first on Investor's Business Daily.

Investors | 1 year ago
Loading...
Load More